| Literature DB >> 16361002 |
Trang V Nguyen1, Lijuan Yuan, Marli S P Azevedo, Kwang-Il Jeong, Ana M Gonzalez, Cristiana Iosef, Karin Lovgren-Bengtsson, Bror Morein, Peggy Lewis, Linda J Saif.
Abstract
We investigated effects of low titer (Lo) circulating MatAb on protection and immunogenicity of attenuated (Att) human rotavirus (HRV) priming and 2/6-virus-like particle (VLP)-immunostimulating complex (ISCOM) boosting (AttHRV/VLP) or VLP-ISCOM alone vaccines. LoMatAb had both enhancing and suppressing effects on B cell responses, depending on tissue, antibody isotype and vaccine. Differential effects of LoMatAb on IgA responses in different tissues suggest that LoMatAb did not suppress induction of IgA effector and memory B cells but impaired homing of these cells to secondary lymphoid or effector tissues, reducing IgA antibody secreting cells and antibodies at these sites. The AttHRV/VLP vaccine partially overcame LoMatAb suppression, conferred moderate protection against virulent HRV (as measured by reduced viral shedding and diarrhea) and represents a new candidate for rotavirus vaccines for both humans and animals.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16361002 DOI： 10.1016/j.vaccine.2005.11.043
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641